{
    "root": "0ea3269c-c917-4b90-8fa1-604c53299ada",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "escitalopram",
    "value": "20250501",
    "ingredients": [
        {
            "name": "ESCITALOPRAM OXALATE",
            "code": "5U85DBW7LO",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_36791"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        }
    ],
    "indications": {
        "text": "escitalopram selective serotonin reuptake inhibitor ( ssri ) indicated : \u2022 treatment major depressive disorder ( mdd ) adults pediatric patients 12 years age older ( 1 ) \u2022 treatment generalized anxiety disorder ( gad ) adults ( 1 )",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "generalized anxiety disorder (DOID:14320)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_14320"
            },
            {
                "text": "anxiety (DOID:2030)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2030"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "indication population recommended mdd adults ( 2.1 ) initial : 10 mg daily recommended : 10 mg daily maximum : 20 mg daily mdd pediatric patients 12 years older ( 2.1 ) initial : 10 mg daily recommended : 10 mg daily maximum : 20 mg daily gad adults ( 2.2 ) initial : 10 mg daily recommended : 10 mg daily maximum : 20 mg daily \u2022 additional benefits seen 20 mg daily ( 2.1 ) \u2022 administer daily , morning evening , without food ( 2.3 ) \u2022 elderly patients : recommended 10 mg daily ( 2.4 ) \u2022 hepatic impairment : recommended 10 mg daily ( 2.4 , 8.6 ) \u2022 discontinuing escitalopram tablets , reduce dose gradually whenever possible ( 2.5 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "\u2022 maois intended treat psychiatric disorders escitalopram within 14 days stopping treatment escitalopram . escitalopram within 14 days stopping maoi intended treat psychiatric disorders . addition , start escitalopram patient treated linezolid intravenous methylene blue ( 4 ) \u2022 concomitant pimozide ( 4 ) \u2022 known hypersensitivity escitalopram citalopram inactive ingredients ( 4 )",
    "indications_original": "Escitalopram is a selective serotonin reuptake inhibitor (SSRI) indicated for the: \u2022 treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older ( 1 ) \u2022 treatment of generalized anxiety disorder (GAD) in adults ( 1 )",
    "contraindications_original": "Indication and Population Recommended Dosage MDD in Adults ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily MDD in Pediatric Patients 12 years and older ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily GAD in Adults ( 2.2 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily \u2022 No additional benefits were seen at 20 mg once daily ( 2.1 ) \u2022 Administer once daily, morning or evening, with or without food ( 2.3 ) \u2022 Elderly patients: recommended dosage is 10 mg once daily ( 2.4 ) \u2022 Hepatic impairment: recommended dosage is 10 mg once daily ( 2.4 , 8.6 ) \u2022 When discontinuing Escitalopram tablets, reduce dose gradually whenever possible ( 2.5 )",
    "adverseReactions_original": "\u2022 Do not use MAOIs intended to treat psychiatric disorders with escitalopram or within 14 days of stopping treatment with escitalopram. Do not use escitalopram within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start escitalopram in a patient who is being treated with linezolid or intravenous methylene blue ( 4 ) \u2022 Concomitant use of pimozide\u00a0( 4 ) \u2022 Known hypersensitivity to escitalopram or citalopram or any of the inactive ingredients ( 4 )",
    "drug": [
        {
            "name": "escitalopram",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_36791"
        }
    ]
}